참고문헌
- Adeli K, Ogbonna G (1990). Rapid purification of human DNA from whole blood for potential application in clinical chemistry laboratories. Clin Chem, 36, 261-4.
- Aldinucci D, Lorenzon D, Cattaruzza L, et al (2008). Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer, 122, 769-76. https://doi.org/10.1002/ijc.23119
- Aoki MN, Da Silva do Amaral Herrera AC, Amarante MK, et al (2009). CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med, 23, 429-35.
- Apostolakis S, Baritaki S, Krambovitis E, Spandidos DA (2005). Distribution of HIV/AIDSprotective SDF1, CCR5 and CCR2 gene variants within cretan population. J Clin Virol, 34, 310-14. https://doi.org/10.1016/j.jcv.2005.01.010
- Arya M, Patel HR, Williamson M (2003). Chemokines: key players in cancer. Curr Med Res Opin, 19, 557-64. https://doi.org/10.1185/030079903125002216
- Balistreri CR, Carruba G, Calabro M, et al (2009). CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily. Ann N Y Acad Sci, 1155, 289-92. https://doi.org/10.1111/j.1749-6632.2008.03691.x
- Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-45. https://doi.org/10.1016/S0140-6736(00)04046-0
-
Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT (1997). Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by CCR5
${\Delta}$ 32. J Biol Chem, 272, 30603-6. https://doi.org/10.1074/jbc.272.49.30603 - Bhasin MK, Walter H, Danker-Hopfe H (1992). The distribution of genetical, morphological and behavioral traits among the peoples of Indian region. Kamla-Raj Publishers, New Delhi.
- Borczuk AC, Papanikolaou N, Toonkel RL, et al (2008). Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES. Oncogene, 27, 557-64. https://doi.org/10.1038/sj.onc.1210662
- Chuang JY, Yang WH, Chen HT, et al (2009). CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol, 220, 418-26. https://doi.org/10.1002/jcp.21783
- Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7. https://doi.org/10.1038/nature01322
- Degerli N, Yilmaz E, Bardakci F (2005). The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem, 38, 248-52. https://doi.org/10.1016/j.clinbiochem.2004.11.001
- Dias S, Choy M, Rafii S (2001). The role of CXC chemokines in the regulation of tumor angiogenesis. Cancer Invest, 19, 732-8. https://doi.org/10.1081/CNV-100106148
- Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA (2006). Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 154, 726-31.
- Erreni M, Bianchi P, Laghi L, et al (2009). Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol, 460, 105-21. https://doi.org/10.1016/S0076-6879(09)05205-7
- Eskandari-Nasab E, Hashemi M, Ebrahimi M, et al (2014). Evaluation of CCL5-403 G>A and CCR5Δ32 gene polymorphisms in patients with breast cancer. Cancer Biomark, 14, 343-51. https://doi.org/10.3233/CBM-140411
- Gawron AJ, Fought AJ, Lissowska J, et al (2011). Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population. Scand J Gastroenterol, 46, 333-40. https://doi.org/10.3109/00365521.2010.537679
- Ghilardi G, Biondi ML, Turri O, et al (2008). Genetic control of chemokines in severe human internal carotid artery stenosis. Cytokine, 41, 24-8. https://doi.org/10.1016/j.cyto.2007.10.007
-
Guleria K, Sharma S, Manjari M, et al (2012). p.R72P, PIN3 Ins16bp Polymorphisms of TP53 and CCR5
${\Delta}$ 32 in North Indian breast cancer patients. Asian Pac J Cancer Prev, 13, 3305-11. https://doi.org/10.7314/APJCP.2012.13.7.3305 - Kaimen-Maciel DR, Reiche EM, Brum Souza DG, et al (2007). CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int J Mol Med, 20, 337-44.
- Kaur S, Sambyal V, Guleria K, et al (2014). Analysis of TP53 polymorphisms in North Indian sporadic esophageal cancer patients. Asian Pac J Cancer Prev, 15, 8413-22. https://doi.org/10.7314/APJCP.2014.15.19.8413
- Libert F, Cochaux P, Beckman G, et al (1998). The delta CCR5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in northeastern Europe. Hum Mol Genet, 7, 399-406. https://doi.org/10.1093/hmg/7.3.399
- Lucotte G (1997). Frequencies of the CC chemokine receptor 5 D32 allele in various populations of defined racial background. Biomed Pharmocother, 51, 469-73. https://doi.org/10.1016/S0753-3322(97)82328-1
- Majumder PP, Dey B (2001). Absence of the HIV-1 protective Delta CCR5 allele in most ethnic populations of India. Eur J Hum Genet, 9, 794-6. https://doi.org/10.1038/sj.ejhg.5200705
- Manes S, Mira E, Colomer R, et al (2003). CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med, 198, 1381-9. https://doi.org/10.1084/jem.20030580
- Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol, 23, 549-55. https://doi.org/10.1016/S1471-4906(02)02302-5
- Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB (1997). Global distribution of the CCR5 gene 32 base pair deletion. Nat Genet, 16, 100-03. https://doi.org/10.1038/ng0597-100
- McDermott DH, Conway SE, Wang T, et al (2010). Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. Blood, 115, 2311-8. https://doi.org/10.1182/blood-2009-08-237768
- Muller A, Homey B, Soto H, et al (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50-6. https://doi.org/10.1038/35065016
- Payne AS, Cornelius LA (2002). The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol, 118, 915-22. https://doi.org/10.1046/j.1523-1747.2002.01725.x
- Perret GY, Crepin M (2008). New pharmacological strategies against metastatic spread. Fundam Clin Pharmacol, 22, 465-92. https://doi.org/10.1111/j.1472-8206.2008.00614.x
- Potteaux S, Combadiere C, Esposito B, et al (2006). Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol, 26, 1858-63. https://doi.org/10.1161/01.ATV.0000231527.22762.71
- Rector A, Vermeire S, Thoelen I, et al (2001). Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum Genet, 108, 190-3. https://doi.org/10.1007/s004390100462
- Seidl H, Richtig E, Tilz H, et al (2007). Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol, 38, 768-80. https://doi.org/10.1016/j.humpath.2006.11.013
- Sidoti A, D'Angelo R, Rinaldi C, et al (2005). Distribution of the mutated delta 32 allele of the CCR5 gene in a Sicilian population. Int J Immunogenet, 32, 193-8. https://doi.org/10.1111/j.1744-313X.2005.00507.x
- Singh H, Sachan R, Jain M, Mittal B (2008). CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res, 17, 87-91. https://doi.org/10.3727/096504008784523667
-
Srivastava A, Pandey SN, Choudhuri G, Mittal B (2008). CCR5
${\Delta}$ 32 polymorphism: associated with gallbladder cancer susceptibility. Scand J Immunol, 67, 516-22. https://doi.org/10.1111/j.1365-3083.2008.02097.x - Stephens JC, Reich DE, Goldstein DB, et al (1998). Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet, 62, 1507-15. https://doi.org/10.1086/301867
- Sugasawa H, Ichikura T, Tsujimoto H, et al (2008). Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol, 97, 445-50. https://doi.org/10.1002/jso.20984
- Sutton A, Friand V, Brule-Donneger S, et al (2007). Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res, 5, 21-33. https://doi.org/10.1158/1541-7786.MCR-06-0103
- Tan MC, Goedegebuure PS, Belt BA, Flaherty, et al (2009). Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol, 182, 1746-55. https://doi.org/10.4049/jimmunol.182.3.1746
- Tanyel CR, Cincin ZB, Gokcen-Rohlig B, et al (2013). Effects of genetic variants of CCR5 chemokine receptors on oral squamous cell carcinoma. Genet Mol Res, 12, 5714-20. https://doi.org/10.4238/2013.November.18.20
- van Deventer HW, O’Connor W Jr, Brickey WJ, et al (2005). C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res, 65, 3374-9. https://doi.org/10.1158/0008-5472.CAN-04-2616
- Veillard NR, Kwak B, Pelli G, et al (2004). Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res, 94, 253-61. https://doi.org/10.1161/01.RES.0000109793.17591.4E
- Velasco-Velazquez M, Jiao X, De La Fuente M, et al (2012). CCR5 Antagonist blocks metastasis of basal breast cancer cells. Cancer Res, 72, 3839-50. https://doi.org/10.1158/0008-5472.CAN-11-3917
- von Luettichau I, Segerer S, Wechselberger A, et al (2008). A complex pattern of chemokine receptor expression is seen in osteosarcoma. BMC Cancer, 8, 23. https://doi.org/10.1186/1471-2407-8-23
- Weng CJ, Chien MH, Lin CW, et al (2010). Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral cancer. Oral Oncol, 46, 767-72. https://doi.org/10.1016/j.oraloncology.2010.07.011
- Wilson J, Balkwill F (2002). The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol, 12, 113-20. https://doi.org/10.1006/scbi.2001.0419
- Yang X, Ahmad T, Gogus F, et al (2004). Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behcet's disease. Eur J Immunogenet, 31, 11-4. https://doi.org/10.1111/j.1365-2370.2004.00444.x
- Zafiropoulos A, Crikas N, Passam AM, Spandidos DA (2004). Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet, 41, 59. https://doi.org/10.1136/jmg.2003.013649
- Zernecke A, Liehn EA, Gao JL, et al (2006). Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood, 107, 4240-3. https://doi.org/10.1182/blood-2005-09-3922
- Zhang X, Haney KM, Richardson AC, et al (2010). Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. Bioorg Med Chem Lett, 20, 4627-30. https://doi.org/10.1016/j.bmcl.2010.06.003
- Zheng B, Wiklund F, Gharizadeh B, et al (2006). Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res, 26, 3669-74.